Bimekizumab efficacy in patients with psoriasis and concurrent hypertension, elevated body mass index, or hyperglycemia: Long-term results from BE BRIGHT

April Armstrong,[1] Steven R. Feldman,[2] Paolo Gisondi,[3] Denis Jullien,[4] Mona Ståhle,[5] Susanne Wiegratz,[6] Nancy Cross,[7] Sarah Kavanagh,[7] Ulrich Mrowietz[8]

[1]University of California Los Angeles (UCLA), Los Angeles, CA, USA; [2]Wake Forest University School of Medicine, Dermatology, Winston-Salem, NC, USA; [3]Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy; [4]Department of Dermatology, Hôpital Edouard Herriot, Hospices Civils de Lyon, University of Lyon, Lyon, France; [5]Department of Medicine, Karolinska Institutet, Solna, Sweden; [6]UCB, Monheim am Rhein, Germany; [7]UCB, Morrisville, NC, USA; [8]Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany

Presentation Number: 63300

OBJECTIVE

- To evaluate the **long-term** efficacy of bimekizumab (BKZ) over 4 years in patients with psoriasis and **concurrent hypertension**, **elevated body mass index (BMI)**, or **hyperglycemia** at baseline.

Background

- Patients with psoriasis exhibit higher cardiometabolic comorbidity rates than the general population;[1] evaluating durable treatment efficacy in these subgroups is important.
- Here, we report ≥90%/100% improvement from baseline in Psoriasis Area and Severity Index (PASI 90/100), and PASI ≤2 response rates over 4 years, in patients with psoriasis and cardiometabolic comorbidities.

Methods

- Data were pooled from the 52-week BE VIVID and the 56-week BE SURE and BE READY phase 3 clinical trials, and their open-label extension (OLE), BE BRIGHT.[2–5]
- Efficacy outcomes were evaluated in patients with psoriasis and concurrent **baseline hypertension**, **elevated BMI**, or **hyperglycemia**.
- Data are reported for patients who received BKZ continuously from baseline into the OLE using modified non-responder imputation (mNRI). Patients discontinuing due to lack of efficacy or treatment-related adverse events were considered non-responders; multiple imputation was used for other missing data.[a]

[a] Patients who entered the BE READY escape arm were considered as non-responders from the date of escape until the end of BE READY, after which they were considered in the same as all other non-escape patients during the BE BRIGHT OLE.

1. Qureshi AA et al. Arch Dermatol 2009;145:379–82; **2.** Reich K et al. Lancet 2021;397:487–98 (NCT03370133); **3.** Warren RB et al. N Engl J Med 2021;385:130–41 (NCT03412747); **4.** Gordon KB et al. Lancet 2021;397:475–86 (NCT03410992); **5.** Strober B et al. Br J Dermatol 2023;188:749–59 (NCT03598790).

BKZ: bimekizumab; BMI: body mass index; mNRI: modified non-responder imputation; OLE: open-label extension; PASI: Psoriasis Area and Severity Index; PASI 90/100: ≥90%/100% improvement from baseline in PASI.

To receive a copy of this poster, scan the QR code.
Link expiration: June 09, 2025

Study Design



Baseline Characteristics

	BKZ Total N=771	Hyper-tension N=375	Elevated BMI N=344	Hyper-glycemia N=62
Age (years), mean (SD)	45.4 (13.5)	47.1 (12.8)	47.5 (12.6)	52.5 (10.8)
Sex, male, n (%)	550 (71.3)	297 (79.2)	244 (70.9)	46 (74.2)
Racial group, white, n (%)	656 (85.1)	322 (85.9)	303 (88.1)	49 (79.0)
Weight (kg), mean (SD)	89.7 (21.2)	94.3 (21.7)	106.5 (17.3)	96.5 (20.7)
BMI (kg/m^2), mean (SD)	29.9 (6.6)	31.1 (6.5)	35.7 (4.7)	32.8 (6.3)
Duration of psoriasis (years), mean (SD)	18.6 (12.7)	19.2 (12.3)	19.7 (13.0)	22.8 (13.8)
PASI, mean (SD)	21.1 (7.6)	21.5 (8.0)	21.5 (7.7)	20.3 (6.3)
BSA (%), mean (SD)	27.0 (15.6)	28.2 (16.5)	27.3 (16.3)	25.0 (12.6)
IGA, n (%)[d]				
3: moderate	508 (65.9)	234 (62.4)	212 (61.6)	42 (67.7)
4: severe	262 (34.0)	141 (37.6)	132 (38.4)	20 (32.3)
DLQI total score, mean (SD)	10.5 (6.3)	10.4 (6.4)	10.5 (6.2)	10.8 (5.6)
Any prior systemic therapy, n (%)	618 (80.2)	304 (81.1)	265 (77.0)	52 (83.9)
Any prior biologic therapy, n (%)	309 (40.1)	144 (38.4)	145 (42.2)	29 (46.8)

[a] BE VIVID did not include an option for Q8W dosing of BKZ during the maintenance period; **[b]** BE VIVID lasted 52 weeks and BE SURE and BE READY lasted 56 weeks; **[c]** At Week 76/80 (OLE Week 24), patients achieving ≥PASI 90 could switch to Q8W at the investigator's discretion; all patients were re-assigned to BKZ Q8W at Week 100/104 (OLE Week 48) or the next scheduled visit via protocol amendment; **[d]** One patient in the BKZ Total group scored IGA 2 at baseline. BKZ: bimekizumab; BMI: body mass index; BSA: body surface area; DLQI: Dermatology Life Quality Index; IGA: Investigator's Global Assessment; OLE: open-label extension; PASI: Psoriasis Area and Severity Index; PASI 90: ≥90% improvement from baseline in PASI; Q4W: every 4 weeks; Q8W: every 8 weeks; SD: standard deviation.

PASI ≤2 Responses Over 4 Years in BKZ-Treated Patients with Comorbidities

Subgroups analyzed

771 BKZ-treated patients with **psoriasis** who entered BE BRIGHT

Measured at baseline

- **Hypertension:** (Systolic >130 mmHg or diastolic >85 mmHg)
- **OR**
- **Elevated BMI:** (BMI >30 kg/m^2)
- **OR**
- **Hyperglycemia:** (Blood glucose ≥140 mg/dL or ≥7.8 mmol/L)





BE VIVID lasted 52 weeks and BE SURE and BE READY lasted 56 weeks; to pool data across studies, Week 56 data were not included. In these figures, the period after Week 52 corresponds to the BE BRIGHT OLE. BKZ: bimekizumab; BMI: body mass index; mNRI: modified non-responder imputation; OLE: open-label extension; PASI: Psoriasis Area and Severity Index.

Scan to access observed case data
Link expiration: June 09, 2025

PASI 90/100 Responses Over 4 Years in BKZ-Treated Patients with Comorbidities





BKZ Total (N=771) | Patients with hypertension (N=375) | Patients with elevated BMI (N=344) | Patients with hyperglycemia (N=62) | Patients with ≥2 comorbidities (N=231)

BE VIVID lasted 52 weeks and BE SURE and BE READY lasted 56 weeks; to pool data across studies, Week 56 data were not included. In these figures, the period after Week 52 corresponds to the BE BRIGHT OLE. BKZ: bimekizumab; BMI: body mass index; mNRI: modified non-responder imputation; OLE: open-label extension; PASI: Psoriasis Area and Severity Index; PASI 90/100: ≥90%/100% improvement from baseline in PASI.

Scan to access observed case data
Link expiration: June 09, 2025

CONCLUSIONS

High rates of complete or near-complete skin clearance were achieved and were durable through 4 years of bimekizumab treatment in patients with psoriasis, regardless of baseline hypertension, elevated BMI, or hyperglycemia.

This benefits patients by demonstrating effective psoriasis management in the context of concurrent cardiometabolic comorbidities.

Author Contributions: Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: **AA**, **SRF**, **PG**, **DJ**, **MS**, **SW**, **NC**, **SK**, and **UM**; Drafting of the publication, or reviewing it critically for important intellectual content: **AA**, **SRF**, **PG**, **DJ**, **MS**, **SW**, **NC**, **SK**, and **UM**; Final approval of the publication: **AA**, **SRF**, **PG**, **DJ**, **MS**, **SW**, **NC**, **SK**, and **UM**.

Disclosures: AA: Served as a research investigator and/or scientific advisor to AbbVie, Almirall, Arcutis, ASLAN, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, EPI, Incyte, Janssen, LEO Pharma, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sun Pharma, Sanofi, and UCB. **SRF:** Received research, speaking and/or consulting support from AbbVie, Advance Medical, Almirall, Alvotech, Bristol Myers Squibb, Boehringer Ingelheim, Caremark, Celgene, Eli Lilly and Company, Galderma, GSK/Stiefel, Informa, Janssen, LEO Pharma, Menlo, Merck, Mylan, National Biological Corporation, National Psoriasis Foundation, Novan, Novartis, Ortho Dermatologics, Qurient, Pfizer, Regeneron, Samsung, Sanofi, Sun Pharma, Suncare Research, and UpToDate; consults for other stakeholders through Guidepoint Global, Gerson Lehrman, and other consulting organizations; founder and majority owner of www.DrScore.com, and founder and part owner of Causa Research, a company dedicated to enhancing patients' adherence to treatment. **PG:** Served as a consultant for AbbVie, Abiogen, Almirall, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Merck, MSD, Novartis, Otsuka, Pfizer, Pierre Fabre, Sanofi, and UCB. **DJ:** Served as a board member and/or consultant for AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius Kabi, Janssen-Cilag, LEO Pharma, Eli Lilly and Company, MSD, MEDAC, Novartis, Pfizer, Sanofi, and UCB; received payment for development of educational presentations including service on speakers' bureaus from AbbVie, Celgene, Janssen-Cilag, LEO Pharma, Eli Lilly and Company, MEDAC, Novartis, and Pfizer; had travel/accommodations expenses covered or reimbursed by AbbVie, Amgen, Biogen, Celgene, Fresenius Kabi, Janssen-Cilag, LEO Pharma, Eli Lilly and Company, MSD, MEDAC, Novartis, Pfizer, Sanofi, and UCB. **MS:** Received honoraria for participating in advisory boards and has given lectures for AbbVie, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Lipidor, Novartis, Pfizer, and UCB. **SW** and **NC:** Employees and shareholders of UCB. **SK:** Served as a consultant for Aclipse Therapeutics, Aliada Therapeutics, Allay Therapeutics, Cognition Therapeutics, Colorado Prevention Center, Karuna Therapeutics, Kisbee Therapeutics, LB Pharma, Nesos, Novartis, Onward, PharPoint Research, Summit Analytical, Tonix, Tornado Therapeutics, UCB, Whitsell Innovations, Worldwide Clinical Trials, and Zosano. **UM:** Served as an advisor and/or clinical study investigator for, and/or received honoraria and/or grants from AbbVie, Aditxt, Almirall, Amgen, Aristea, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dr. Reddy's, Eli Lilly and Company, Formycon, Immunic, Janssen-Cilag, LEO Pharma, Merck, Sharp & Dohme, MetrioPharm, Novartis, Phi-Stone, Sanofi-Aventis, UCB, and UNION therapeutics.

Acknowledgements: This study was funded by UCB. We would like to thank the patients and their caregivers in addition to all the investigators and their teams who contributed to this study. The authors acknowledge Inés Dueñas Pousa, UCB, Madrid, Spain, for publication coordination, Delphine Deherder, UCB, Braine-l'Alleud, Belgium, for input on design of the analysis, and Calum Suggett, MSc, Costello Medical, London, UK for medical writing support and editorial assistance. All costs associated with development of this presentation were funded by UCB.